SYF

Synchrony Financial

$72.02

+0.45%
Nov 11, 2026
Bobby Quantitative Model
Synchrony Financial is the largest provider of private-label and co-branded credit cards in the United States, operating through three segments — Retail Card (partner-branded cards for retailers and e-commerce platforms), Payment Solutions (promotional financing for big-ticket purchases), and CareCredit (financing for elective healthcare procedures) — and functions as a consumer lender within the Financial Services sector. Its competitive identity rests on deep, sticky merchant partnerships and a data-driven underwriting engine rather than a deposit-heavy branch network, making it a scaled but partner-dependent niche leader in consumer credit. The current investor narrative centers on three threads: management's raised full-year earnings guidance and new AI-driven partnership initiatives highlighted in recent coverage, improving credit metrics that suggest the everyday consumer is holding up despite inflation, and an aggressive capital-return program (roughly $1.1 billion of buybacks in Q3 alone) that is shrinking the share count and flattering EPS. Offsetting this optimism is a persistent valuation debate — the stock trades at a single-digit earnings multiple even after a modest one-year gain, reflecting investor caution over consumer credit risk and the stock's notable year-to-date underperformance.

People also watch

Visa Inc.

Visa Inc.

V

Analysis
Mastercard

Mastercard

MA

Analysis
American Express

American Express

AXP

Analysis
Capital One

Capital One

COF

Analysis
PayPal Holdings

PayPal Holdings

PYPL

Analysis

BobbyInvestment Opinion: Should I buy SYF Today?

Rating: Buy (moderate conviction). Synchrony offers roughly 18% upside to the $87.00 average analyst target from $73.74, with all 23 covering analysts — 14 Buy, 9 Hold, 0 Sell — carrying targets above the current price (floor $76.00), and the core thesis is that a 7.03x forward PE and 1.09 PEG already discount a consumer credit deterioration that has not materialized, while improving credit metrics and a shrinking share count drive ~21% forward EPS expansion. The stock is a valuation-plus-capital-return story, not a growth story, and the consensus recommendation score of 1.96 (buy territory) is consistent with that framing.

Supporting evidence is concrete: the forward multiple of 7.03x versus 8.92x trailing implies the market expects earnings to grow into the valuation, and the 1.78x price-to-book and 1.56x price-to-sales are modest against a 21.19% ROE and 24.17% operating margin. Sequential profitability is genuinely improving — gross margin rose from 50.6% in Q1 to 53.2% in Q3 and operating margin from 22.44% to 24.62% — while Q3 free cash flow of $2.498 billion (TTM $9.555 billion) comfortably funds $1.1 billion of quarterly buybacks and a 1.71% dividend yield. Diluted shares fell from 389.4 million in Q1 2025 to 322.4 million in Q3 2026, a ~17% reduction that mechanically supports the $12.80 consensus EPS against a flat $4.797 billion revenue base (down 0.77% YoY).

The biggest risks that could invalidate the thesis are a consumer credit shock (Q3 interest expense of $979 million against $1.181 billion operating income leaves only ~1.2x coverage), a stall in the buyback-driven EPS math, and multiple compression given the 8.92x PE already sits in the upper-middle of its 3.3x–10.1x historical band. This Buy would upgrade to higher conviction if net income returns above the prior-year $1.077 billion while revenue stabilizes, and would downgrade to Hold if credit costs push net income below the $805 million Q1 trough or if the forward EPS estimate of $12.80 is cut. Verdict: fairly valued to modestly undervalued relative to its own history and clearly discounted versus Credit Services peers — cheap on absolute multiples, but not the deep-value bargain it was at 3.3x in 2024.

Sign up to view all

SYF 12-Month Price Forecast

The forward setup is asymmetric in Synchrony's favor: a 7.03x forward multiple, a $76.00 analyst floor above the current price, and zero Sell ratings mean the Street has effectively priced a floor near current levels while leaving ~18% to the $87.00 average target. The catch is that the earnings growth implied by the forward multiple depends on credit costs staying contained and the buyback continuing — revenue is flat at $4.797 billion (down 0.77% YoY) and net income of $892 million still trails the prior-year $1.077 billion, so the thesis is about normalization and capital return rather than organic growth. The 8.92x trailing PE sitting in the upper-middle of its 3.3x–10.1x historical band limits re-rating upside, which is why confidence is medium rather than high. I would upgrade to high confidence if Q4 net income returns above $1.0 billion with revenue stabilizing, and downgrade to neutral if charge-offs rise enough to push net income back toward the $805 million Q1 trough or if the $12.80 consensus EPS is cut.

Historical Price
Current Price $72.02
Average Target $81.50
High Target $103.00
Low Target $63.08

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Synchrony Financial's 12-month outlook, with a consensus price target around $87.00 and implied upside of +20.8% versus the current price.

Average Target

$87.00

23 analysts

Implied Upside

+20.8%

vs. current price

Analyst Count

23

covering this stock

Price Range

$76 - $103

Analyst target range

Buy
14 (61%)
Hold
9 (39%)
Sell
0 (0%)

Coverage is broad and constructive: 23 analysts rate the stock, with 14 Buy, 9 Hold, and 0 Sell, producing a consensus recommendation of "buy" (mean score 1.96 on a 1-to-5 scale where lower is more bullish). The average target price of $87.00 implies roughly 18% upside from the $73.74 current price, and notably even the lowest target of $76.00 sits above the current price — a signal that the Street sees the stock as undervalued at these levels. The consensus leans bullish but not euphoric, with the nine Hold ratings reflecting lingering caution on consumer credit and the flat revenue trajectory. The target range of $76.00 to $103.00 is wide — a 36% spread from low to high — indicating meaningful disagreement about the earnings trajectory. The $103 high target likely assumes multiple expansion toward historical norms, successful AI partnership monetization, continued credit improvement, and full delivery of the raised guidance, while the $76 low target prices in a more conservative scenario of margin compression and elevated credit costs with little re-rating. Recent institutional actions show a stable-to-mixed tone: Barclays, TD Cowen, Evercore ISI, and Wolfe Research maintain Overweight/Outperform/Buy ratings, while UBS, JP Morgan, and Morgan Stanley remain Neutral/Equal Weight, and Evercore's October shift from Outperform to In Line is a mild caution flag. The estimated EPS average of $12.80 (range $12.48–$13.10) against the $73.74 price implies a forward multiple near 5.8x on consensus numbers, reinforcing that the stock is cheap if those estimates hold — the wide target spread and split Buy/Hold distribution suggest conviction is moderate rather than high, consistent with a stock whose fate hinges on consumer credit quality.

Drowning in data?

Find the real signal!

Bulls vs Bears: SYF Investment Factors

The bear case currently has slightly stronger near-term evidence: revenue is flat to down, year-over-year net income fell from $1.077B to $892M, and the stock has badly lagged the market with a -12.89% YTD return against SPY's +7.83%. The bull case, however, rests on harder valuation math — a 7.03x forward PE, a 1.09 PEG, 21.19% ROE, and an analyst floor of $76.00 with zero Sell ratings — and on a genuine sequential margin recovery from 50.6% to 53.2% gross margin. The single most important tension is whether the ~21% EPS expansion embedded in the forward multiple materializes: if credit costs stay contained and the buyback keeps shrinking the share count, the stock is cheap; if consumer credit deteriorates, the forward earnings number is an illusion and the multiple is not as low as it appears. Everything else — AI partnerships, the guidance raise, technical levels — is secondary to that one credit-quality question.

Bullish

  • Street sees no downside to current price: All 23 covering analysts have targets above the $73.74 current price — the lowest target is $76.00, and the $87.00 average implies roughly 18% upside. With 14 Buy ratings, 9 Hold, and zero Sell, the consensus recommendation score of 1.96 is firmly in buy territory, and the absence of any sell rating is a strong signal that professional coverage views the current level as a floor rather than a ceiling.
  • Deep discount to sector on profitability: At 8.92x trailing and 7.03x forward earnings, Synchrony trades well below what Credit Services peers command despite a 21.19% ROE and 24.17% operating margin. The 1.78x price-to-book and 1.56x price-to-sales are similarly modest, and the 1.09 PEG ratio implies growth is being paid for at close to fair value — the market is pricing consumer credit risk, not disputing business quality.
  • Sequential margin expansion is real: Gross margin climbed from 50.6% in Q1 to 53.2% in Q3, and operating margin rose from 22.44% in Q1 to 24.62% in Q3 (versus 19.97% in Q4 2025). Net income improved sequentially from $805M in Q1 to $885M in Q2 to $892M in Q3, showing credit-loss normalization and expense discipline are flowing through to the bottom line.
  • Massive buyback shrinking share count: Diluted shares fell from 389.4M in Q1 2025 to 322.4M in Q3 2026 — a roughly 17% reduction — with $1.1 billion repurchased in Q3 alone, funded comfortably by $9.555 billion TTM free cash flow. This mechanical EPS tailwind is a key reason consensus forward EPS of $12.80 implies ~21% expansion even with flat revenue.

Bearish

  • Revenue is flat and slightly shrinking: Q3 2026 revenue of $4.797 billion was down 0.77% year-over-year, and quarterly revenue has hovered between $4.67B and $4.80B for six straight quarters. With no segment disclosure, there is no visibility into which of Retail Card, Payment Solutions, or CareCredit is the marginal drag — the entire earnings story rests on margin, credit, and buybacks rather than growth.
  • Year-over-year earnings still compressing: Q3 2026 net income of $892 million is well below the $1.077 billion earned in Q3 2025, and diluted EPS of $2.68 trails the prior-year $2.86 despite the smaller share count. Sequential improvement masks a real earnings decline, and the forward PE of 7.03x bakes in ~21% EPS expansion that has not yet appeared in reported results.
  • Thin interest coverage amplifies credit risk: Q3 interest expense of $979 million against $1.181 billion of operating income leaves interest coverage of roughly 1.2x — a thin cushion for a spread-based lender. A spike in funding costs or a deterioration in consumer credit would hit earnings disproportionately, and the 0.21 current ratio reflects a funding structure with little short-term liquidity buffer.
  • Multiple already mid-to-high in historical band: Synchrony's PE has ranged from roughly 3.3x in Q1 2024 to 10.1x in Q4 2025, and the current 8.92x sits in the upper-middle of that band. The market is already pricing a benign credit environment and successful delivery of the guidance raise, leaving limited room for multiple expansion and more vulnerability if credit trends reverse.

SYF Technical Analysis

Synchrony is in a range-bound consolidation phase rather than a clean trend: the stock is up 25.83% over the past year but down 12.89% year-to-date, and at $73.74 it sits at roughly 41% of its 52-week range (low $63.08 to high $88.77). That mid-to-lower positioning signals neither momentum-driven overextension nor a falling-knife collapse — it is a stock that rallied hard off its lows, stalled well below its highs, and is now chopping sideways. The 27.91% maximum drawdown underscores how violently the range has been tested, and the fact that price is 16.9% below the 52-week high means overhead supply remains a real obstacle. Recent momentum is tentatively improving but fragile: the stock is up 2.52% over the past month versus a 4.99% decline in SPY, a 7.51-point relative-strength outperformance, yet it is down 6.17% over three months (roughly 1.26 points worse than SPY). This divergence — positive one-month, negative three-month, positive one-year — is classic mean-reversion behavior within a consolidation, with the October rebound from the ~$70.67 late-September low showing buyers defending the low-$70s. The 4.9 million share volume and 5.38 short ratio indicate moderate but not extreme bearish positioning, suggesting the recent bounce has room to extend without a squeeze dynamic. Key levels are clear: support clusters at the $70.67–$71.50 area with the $63.08 52-week low as the line in the sand, while resistance sits at the $80–$81 August highs and then the $88.77 52-week high. A breakout above $81 would confirm a new leg higher and likely target the prior high, whereas a breakdown below $70 would re-open the path toward the $63 low and signal that the year-to-date downtrend has resumed. With a beta of 1.395, the stock is roughly 40% more volatile than the market, meaning position sizing should account for amplified drawdowns — a 10% SPY move implies a ~14% move here, which matters for stop placement and risk budgeting.

Beta

1.40

1.40x market volatility

Max Drawdown

-27.9%

Largest decline past year

52-Week Range

$63-$89

Price range past year

Annual Return

-3.2%

Cumulative gain past year

PeriodSYF ReturnS&P 500
1m-2.2%-2.4%
3m-10.1%-2.3%
6m+0.9%+2.8%
1y-3.2%+11.3%
ytd-14.9%+11.4%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

SYF Fundamental Analysis

Revenue is essentially flat and slightly decelerating: Q3 2026 revenue of $4.797 billion was down 0.77% year-over-year versus $4.834 billion in Q3 2025, continuing a pattern of sequential stagnation ($4.666B in Q1, $4.693B in Q2, $4.797B in Q3) after a full-year 2025 that saw quarterly revenue hover between $4.7B and $4.8B. The top line is being held back by a shrinking balance-sheet footprint as management prioritizes credit discipline over volume growth, and the absence of segment disclosure limits visibility into whether Retail Card, Payment Solutions, or CareCredit is the marginal drag. For the investment case, flat revenue means the earnings story must be driven by margin, credit-loss normalization, and buybacks rather than organic growth — a lower-quality but still workable formula if credit trends hold. Profitability is solid and improving: Q3 2026 net income of $892 million on a 18.59% net margin and 53.2% gross margin, with operating margin at 24.62% versus 22.44% in Q1 and 19.97% in Q4 2025, showing clear sequential margin expansion. Gross margin has climbed from 50.6% in Q1 to 53.2% in Q3, and the 24.17% operating margin and 18.58% net margin are healthy for a consumer lender, though net income of $892M is still below the $1.077B earned in Q3 2025 — a reminder that year-over-year earnings are compressing even as sequential trends improve. The trajectory is one of stabilization rather than breakout: losses are not widening, but the company has not yet returned to prior-year profit levels. The balance sheet is leveraged but manageable for a lender: debt-to-equity of 0.91, a 21.19% ROE, and a low 2.78% ROA that is typical of a spread-based credit business, while the 0.21 current ratio reflects the funding structure rather than distress. Free cash flow is robust — $9.555 billion TTM and $2.498 billion in Q3 alone — comfortably covering $1.1 billion of quarterly buybacks and $138 million of dividends, and the 3.03 price-to-cash-flow ratio implies the market is paying little for that cash generation. The main financial risk is funding and credit cost: interest expense of $979 million in Q3 against $1.181 billion of operating income leaves thin interest coverage, so a deterioration in consumer credit or a spike in funding costs would hit earnings disproportionately.

Quarterly Revenue

$4.8B

2026-09

Revenue YoY Growth

-0.8%

YoY Comparison

Gross Margin

53.2%

Latest Quarter

Free Cash Flow

$9.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Open an Account, get $2 TSLA now!

Valuation Analysis: Is SYF Overvalued?

Because Synchrony is profitable (Q3 net income of $892 million), the PE ratio is the appropriate primary metric, and the 8.92x trailing PE versus 7.03x forward PE is the key signal: the market expects earnings to grow into the multiple, with the forward discount implying roughly 21% EPS expansion is already priced in. The 1.09 PEG ratio suggests that growth is being paid for at close to fair value, and the 1.78 price-to-book and 1.56 price-to-sales ratios are modest for a financial with a 21.19% ROE. The gap between trailing and forward multiples is the crux — if the projected EPS materializes, the stock is cheap; if credit costs surprise, the forward number is at risk. Against the Financial Services / Credit Services industry, Synchrony trades at a meaningful discount: its 8.92x trailing PE and 1.78x P/B are well below what the sector typically commands for comparable profitability, and its 5.85x EV/EBITDA and 2.64x EV/Sales are similarly low. The discount is partly structural — private-label credit is viewed as more cyclical and partner-concentrated than diversified card issuers — but with a 51.04% gross margin, 24.17% operating margin, and 1.71% dividend yield, the valuation looks inexpensive relative to its profitability, suggesting the market is pricing in consumer credit risk rather than disputing the business quality. Historically, Synchrony's PE has ranged from roughly 3.3x (Q1 2024) to 10.1x (Q4 2025), and the current 8.92x sits in the upper-middle of that band — closer to the high end than the low. That positioning implies the market is already pricing in a benign credit environment and successful execution of the guidance raise, leaving less room for multiple expansion and more vulnerability if credit trends reverse; the stock is not the deep-value bargain it was in 2024, but it is also not expensive on absolute terms.

PE

8.9x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 3x~10x

vs. Industry Avg

14.2x

Industry PE ~14.2x*

EV/EBITDA

5.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the lender's thin interest coverage and flat top line. Q3 interest expense of $979 million consumed roughly 83% of the $1.181 billion in operating income, leaving little cushion if funding costs rise or credit losses normalize upward. Revenue of $4.797 billion was down 0.77% year-over-year and has stagnated between $4.67B and $4.80B for six quarters, meaning earnings growth depends entirely on margin expansion and the buyback rather than organic volume. The 17% reduction in diluted shares (389.4M to 322.4M) flatters EPS but is a finite lever, and net income of $892 million remains below the $1.077 billion earned a year earlier. Concentration in private-label retail and elective healthcare financing also ties results to discretionary consumer spending, which is the first thing to crack in a downturn.

Market and competitive risks are dominated by the structural discount applied to private-label credit. At 8.92x trailing and 7.03x forward earnings, the stock trades below diversified card issuers because investors view partner-concentrated, cyclical receivables as riskier — and that discount can persist or widen. The 8.92x multiple sits in the upper-middle of its historical 3.3x-to-10.1x band, so the easy re-rating has already happened and further compression is a live risk if credit trends reverse. With a beta of 1.395, a 10% market decline implies roughly a 14% move here, and the stock's -20.72-point YTD relative-strength gap versus SPY shows it is already being sold in rotations away from consumer credit. Evercore's October downgrade from Outperform to In Line, alongside Neutral stances from UBS, JPMorgan, and Morgan Stanley, signals that even the sell side is split on near-term catalysts.

In a worst-case scenario, a weakening consumer drives charge-offs higher, forcing Synchrony to build reserves and compress margins just as the forward EPS estimate of $12.80 is being relied upon. That combination would simultaneously hit earnings and the multiple, pushing the stock toward its $63.08 52-week low — roughly -14.5% from $73.74 — and a deeper credit cycle could test below that level given the 27.91% max drawdown already experienced. The analyst low target of $76.00 offers little downside protection because it sits above the current price, meaning the Street has not modeled a genuine credit shock. An investor should size positions assuming a realistic -15% to -25% drawdown in an adverse scenario, amplified by the 1.395 beta if the broader market also sells off.

FAQ

The most severe risk is credit and funding: Q3 interest expense of $979 million consumed roughly 83% of $1.181 billion in operating income, leaving interest coverage near 1.2x, so a charge-off spike or funding-cost increase would hit earnings disproportionately and invalidate the $12.80 consensus EPS. Second is earnings quality — revenue of $4.797 billion is down 0.77% year-over-year and has stagnated for six quarters, while net income of $892 million trails the prior-year $1.077 billion, meaning growth depends on a finite buyback lever (shares already down ~17% to 322.4M) rather than organic volume. Third is valuation and market risk: the 8.92x PE sits in the upper-middle of its 3.3x-10.1x historical band, and with a 1.395 beta a 10% market decline implies roughly a 14% move here, compounded by a -20.72-point year-to-date relative-strength gap versus SPY. Fourth is company-specific concentration — as the largest US private-label card issuer, Synchrony is tied to discretionary retail and elective healthcare spending and to the retention of major merchant partners, and the absence of segment disclosure limits visibility into which portfolio is the marginal drag.

The scenario framework is 55% base, 25% bull, and 20% bear. The base case targets $76-$87, assuming revenue stays in the $4.67B-$4.80B range, gross margin holds at or above 53.2%, buybacks continue near $1 billion per quarter, and the stock drifts toward the $87.00 average target as the 7x-9x multiple holds. The bull case targets $87-$103 and requires credit costs to stay contained, net income to return above the prior-year $1.077 billion, and AI-driven partnership monetization to add a growth narrative, closing part of the discount to diversified card issuers. The bear case targets $63.08-$76.00, with a weakening consumer driving charge-offs and reserve builds that compress margins, invalidate the $12.80 EPS estimate, and retest the 52-week low — roughly -14.5% from $73.74, amplified by the 1.395 beta. The base case is most likely because all 23 analyst targets sit above the current price and sequential margins are already improving, but the key assumption is that credit normalization proves durable rather than a one-quarter improvement.

Synchrony screens cheap on absolute and relative measures: 8.92x trailing and 7.03x forward earnings, 1.78x price-to-book, 1.56x price-to-sales, 5.85x EV/EBITDA, and a 1.09 PEG, all well below what Credit Services peers command despite a 21.19% ROE and 24.17% operating margin. The forward discount to trailing implies the market already expects roughly 21% EPS growth, so the stock is not a pure deep-value bargain — its own PE history has ranged from about 3.3x in Q1 2024 to 10.1x in Q4 2025, and the current 8.92x sits in the upper-middle of that band, meaning the easy re-rating has already occurred. The market is therefore paying a modest premium to the stock's own recent trough but a clear discount to peers, which implies investors are pricing consumer credit risk and partner concentration rather than disputing business quality. Verdict: fairly valued to modestly undervalued versus its own history and discounted versus the sector — cheap enough to own, not cheap enough to be a table-pounding value trade.

On a risk/reward basis the setup is moderately attractive: at $73.74 the stock sits roughly 18% below the $87.00 average analyst target, and even the lowest of the 23 targets ($76.00) is above the current price with zero Sell ratings, so the Street is effectively underwriting a floor near today's level. The valuation support is real — 7.03x forward earnings, a 1.09 PEG, 1.78x book, and a 21.19% ROE — and sequential margins have improved from 50.6% to 53.2% gross and 22.44% to 24.62% operating between Q1 and Q3 2026. The catch is that the ~21% EPS expansion implied by the forward multiple depends on credit costs staying contained while revenue is flat at $4.797 billion (down 0.77% YoY) and net income of $892 million still trails the prior-year $1.077 billion. The biggest downside risk is a consumer credit shock that forces reserve builds and compresses the multiple simultaneously, with the $63.08 52-week low representing roughly -14.5% from here. It is a good buy for value-oriented investors with a 12-24 month horizon who can tolerate a 1.395 beta and a potential -15% to -25% drawdown, but not for those needing growth or low volatility.

Synchrony fits a medium-to-long-term holding period of at least 12-24 months rather than short-term trading. The earnings case is a normalization and capital-return story — margin recovery from 50.6% to 53.2% gross, a share count down ~17% to 322.4M, and $9.555 billion in TTM free cash flow funding $1.1 billion quarterly buybacks and a 1.71% dividend yield — all of which compound over multiple quarters rather than days. The stock is not a low-volatility income substitute: beta is 1.395, the max drawdown has been 27.91%, and the 52-week range of $63.08-$88.77 is wide, so short-term holders face amplified swings tied to monthly credit data and rate expectations. Earnings visibility is moderate — revenue is flat and there is no segment disclosure, but the 23-analyst coverage with a $76.00 floor and zero Sell ratings provides a sentiment anchor. A reasonable approach is a staged entry near the $70.67-$71.50 support zone with a 12-24 month horizon, reassessing if net income falls back toward the $805 million Q1 trough or if the $12.80 forward EPS estimate is cut.